Information  X 
Enter a valid email address

PureTech Health PLC (PRTC)

  Print      Mail a friend

Monday 14 September, 2015

PureTech Health PLC

Appoints Michael MacLean as CFO

RNS Number : 8978Y
PureTech Health PLC
14 September 2015
 



14 September 2015

 

PureTech Health plc

 

PureTech Appoints Michael MacLean as Chief Financial Officer

 

PureTech Health plc ("PureTech" or the "Company", LSE: PRTC), a science-driven healthcare company seeking to develop disruptive solutions to address unmet medical needs and improve the lives of patients, today announced that Michael MacLean has been appointed to PureTech's management team as Chief Financial Officer and Executive Vice President.

 

Michael MacLean joins PureTech from Iron Mountain Inc. (NYSE: IRM), the FORTUNE 1000 global storage and information management company, where he was Chief Financial Officer of its North American business overseeing $2.2bn of annual revenue and approximately $1bn of EBITDA.  Previously, Mr. MacLean was Senior Vice President, Finance and Chief Accounting Officer at Biogen (NASDAQ: BIIB), a global biopharmaceutical company with annual revenues of more than $9bn, during which time he managed many of the finance and accounting functions and was responsible for structuring and managing collaborations and strategic acquisitions. He also was an audit partner at global public accounting firms including KPMG, one of the largest professional services companies in the world where he supported global clients in industries including pharmaceuticals, medical devices and diagnostics.

 

Daphne Zohar Co-Founder and CEO of PureTech commented:

"We are pleased to welcome Michael to PureTech as our Chief Financial Officer.  His wealth of experience in finance and accounting across multiple disciplines, including deal structuring and acquisitions in the healthcare sector, will be a great addition to PureTech as our growth stage companies move towards commercialization."

 

Michael MacLean commented:

"In my various roles, I've looked closely at many businesses in the healthcare sector and PureTech stands out as truly innovative. I look forward to joining the stellar PureTech team and contributing during this exciting phase of growth for the Company."

 

For further information please contact:

 

PureTech


Julie DiCarlo, Senior Vice President, Communications and Investor Relations

 

+1 617 456 0032

FTI Consulting (Communications adviser to PureTech)

Ben Atwell / Matthew Cole

 

+44 (0)20 3727 1000

 

 


About PureTech

 

PureTech (PureTech Health plc, PRTC.L) is a science-driven healthcare company, seeking to solve some of today's toughest health challenges through disruptive approaches. Based in Boston, Massachusetts, PureTech has a pipeline of 12 operating companies, seven of which are "growth stage" with external validation including strategic partnerships, outside funding, proof-of-concept or peer review in prestigious scientific journals. PureTech is problem-focused and solution-agnostic, looking beyond traditional disciplines and approaching healthcare problems from different perspectives. Focusing on areas of significant unmet medical need, PureTech evaluates more than 650 ideas per year, prioritizing, selecting and  testing what it believes to be the most scientifically and commercially promising concepts to advance. PureTech's leading team and board, along with an advisory network of more than 50 experts across multiple disciplines, gives PureTech access to potentially groundbreaking science and technological innovations. For more information, visit www.puretechhealth.com and connect with us on Twitter.

 

PureTech Forward-Looking Statement

 

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the company's regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law, regulatory requirement, the Listing Rules and the Disclosure and Transparency Rules, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

###


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLJMMTMBJBTAA

a d v e r t i s e m e n t